Champions Oncology Stock
Champions Oncology, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Robert Brainin
- Employees
- 214
- Market cap
- $65 M
- IPO
- 02/02/2007
Champions Oncology, Inc. is dedicated to developing and commercializing cutting-edge technological products and services designed to personalize cancer treatment and streamline the development of oncology drugs across the United States. At the heart of its offerings is the Tumorgraft Technology Platform, an innovative…
Champions Oncology stock: price history
1D
-1.9%
1W
-2.9%
1M
-5.1%
6M
-22.2%
YTD
-32.0%
1Y
-28.4%
2Y
+3.1%
5Y
-53.4%
10Y
+176.8%
Next earnings date
Next earnings date
15/12/2026 (in 59 days)
Volatility around earnings
~4% weaker price swings than usual
Ask the agents about Champions Oncology
Analyst assessment of Champions Oncology
PRICE TARGET LOW
US$12.00
CONSENSUS
US$12.00
MEDIAN
US$12.00
PRICE TARGET HIGH
US$12.00
0
STRONG BUY
5
BUY
2
HOLD
0
SELL
0
STRONG SELL
7
TOTAL · Buy
As of: 12/03/2025
Champions Oncology stock metrics
P/E
-59.49
P/B
16.78
EV/EBITDA
161.14
RETURN ON EQUITY
-10.9%
NET MARGIN
-2.8%
DEBT/EQUITY
2.82
DIVIDEND YIELD
0.0%
AS OF
31/07/2026
Free float & liquidity
FREE FLOAT
37.4%
FLOAT SHARES
5,200,265
AVG. DAILY VOLUME (30D)
12,881
Insider transactions (SEC)
ACKERMAN JOEL
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Champions Oncology stock
What does Champions Oncology do?
Champions Oncology, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Robert Brainin, the company employs around 214 people.
The IPO was on 02/02/2007; the stock trades on NASDAQ under the ticker CSBR.
What do analysts say about Champions Oncology stock?
7 analysts rate the stock, the consensus is Buy (as of 12/03/2025).
The average price target is US$12.00, ranging from US$12.00 to US$12.00, with a median of US$12.00.
This is an external assessment, not a statement by Market Jury.
When does Champions Oncology report next?
The next earnings date is 15/12/2026.
Around past earnings, price swings were roughly -4% stronger than usual.
Does Champions Oncology pay a dividend?
No, Champions Oncology currently does not pay a dividend.
Which stocks are comparable to Champions Oncology?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Champions Oncology stock analyzed?
Clicking "Analyze stock" lets five strategies assess Champions Oncology against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.